IPS is a leading provider of Technical Consulting, Design, Engineering, Construction, Project Controls, Commissioning and Qualification services for technically complex facilities worldwide.
We are internationally recognized as experts in advanced aseptic processing and risk-based isolation and barrier technologies. Our experience, awareness and understanding of industry trends places importance on time-to-market, plant flexibility and cost control to avoid costly project delays and minimize risk.
Whether the products are new or existing, our Drug Development and Technology Transfer services offer solutions that consistently maintain quality and compliance to effectively accelerate scale-up through market launch. Our experts provide ideas that speed pharmaceutical and biotech products to market.
Our team has the experience and technical knowledge to execute the most complex, demanding laboratory projects. Our unique approach combines the design elements with operational excellence, energy efficiency and risk and safety assessment as required to meet your laboratory needs.
Knowing the technology, industry trends, regulatory environment and manufacturing processes enables our process/bioprocess engineers to identify opportunities to streamline production and maximize efficiency.
With technical expertise spanning R&D to pilot-scale and large-scale production, our team knows the technology, trends and regulatory environment to successfully deliver any sized project. Our unique approach and technical expertise enables us to significantly improve operational capabilities, throughput and process control, optimize cost and minimize risk.
With biomanufacturing technical expertise spanning R&D to pilot-scale and large-scale production, our team knows the technology, trends and regulatory environment to successfully deliver any sized project. Our unique approach and technical expertise enables us to significantly improve operational capabilities, throughput and process control, optimize cost and minimize risk.
We provide the knowledge, flexibility and technical expertise through our risk-based approach designed to reduce risk, lower costs, improve efficiency and productivity and comply with mandates and requirements. We minimize the impact of operations through energy management programs and our unique solutions to modernize facilities and reduce the environmental footprint.
For over twenty-five years, IPS has delivered fully integrated Engineering, Construction, Project Controls, Commissioning and Qualification services to the pharmaceutical industry. Our team imparts Knowledge, Skill and Passion to develop solutions that improve efficiency, productivity, financial performance and minimize overall cost and risk.
Integrated Project Services (IPS)
721 Arbor Way, Suite 100
Blue Bell, PA 19422
UNITED STATES
Phone: 610.828.4090
Contact: Sales
IPS-Integrated Project Services, LLC (IPS), a leading provider of Engineering, Procurement, Construction Management and Validation (EPCMV) services, announces the ninth annual IPS Technologies Tours at INTERPHEX with Tours focused on the hottest trends in the industry, including Pharma 4.0 concepts, cell processing, and gene therapy.
Expansions and renovations to existing biological facilities, and construction of new facilities, provide a unique opportunity to rethink basic design strategies and use new technologies to build a better facility that will improve compliance. This article is the sixth in a six-part series on how single-use systems (SUS) are changing the modern biotechnology facility design and construction paradigm.
Cell therapies have the potential to revolutionize the biopharmaceutical world, but today’s processes, logistics, and delivery make for a challenging entry into the sector’s growth curve. As the industry evolves, we have to answer (at least) three important questions when bringing these exciting new therapies to market.
In 1931, Swiss doctor Paul Niehans injected a preparation of live cells from a parathyroid gland into a dying patient. The patient subsequently recovered, and Dr. Niehans had a eureka moment — that injections of living cells can have tremendous therapeutic value.
Pharmaceutical plants cannot be treated like real estate. Instead, they require a detailed assessment of where they are in “operational compliance and production readiness.”
In part 1 of our article on biocontainment, we discussed the history of biocontainment as an outgrowth of medical research, especially the effort to develop vaccines for various worldwide diseases. We provided some definition of the biosafety levels (BSLs) established by the Centers for Disease Control and Prevention (CDC) based on risk considerations. We also discussed the regulatory regime for biological agents and, specifically, for designing a facility for an FDA or EU regulated product within the confines of the safety practices dictated by the CDC and design requirements of the NIH.
Expansions and renovations to existing biological facilities, and construction of new facilities, provide a unique opportunity to rethink basic design strategies and use new technologies to build a better facility that will improve compliance. This article is the third in a six-part series on how single-use systems are changing the modern biotechnology facility and process design paradigm.
This article explores modern facility design principles that make use of the most flexible new technologies and provide a platform to rein in costs, reduce schedules, and deliver products compliantly and within business risk tolerance.
Today’s disposable systems offer improved manufacturing efficiency, and better QA and regulatory compliance — and they can be the fastest route to media fills
The movement of viral vectors, cell therapies and other antibody-based next-generation drug products toward commercialization is driving the need for new and different technologies and facilities. Engineering and design firms with the right skill sets can help you maintain the right balance in your facility design to maintain flexibility which is essential to meet diverse processing needs for biopharmaceutical manufacturing.
IPS-Integrated Project Services, LLC and G-CON Manufacturing, Inc. announced recently that the iCON™ product portfolio now has a second manufacturing site in Kilkenny, Ireland, through the Manufacturing and Supply Agreement between G-CON and Asgard Cleanroom Solutions Ltd.
IPS-Integrated Project Services, LLC (IPS), a leading global provider of engineering, architecture, project controls, construction management, commissioning and qualification services, and G-CON Manufacturing, Inc. the leading provider of prefabricated cleanrooms, announced the unveiling of the iCON™ brand which represents the collective facility design and build capabilities of the two companies.
